Experimental. Shall be defined as all procedures and treatments not covered under the Medicare Program (Title XVlll of Social Security Act of 1965, as amended), unless otherwise specifically included or excluded under this Agreement.
Experimental. INVESTIGATIVE - the use of any treatment, Service, procedure, facility, equipment, drug, device or supply (intervention) which is not determined by the Plan to be medically effective for the condition being treated. The Plan will consider an intervention to be Experimental/Investigative if:
a. the intervention does not have FDA approval to be marketed for the specific relevant indication(s); or
b. available scientific evidence does not permit conclusions concerning the effect of the intervention on health outcomes; or
c. the intervention is not proven to be as safe and as effective in achieving an outcome equal to or exceeding the outcome of alternative therapies; or
d. the intervention does not improve health outcomes; or
e. the intervention is not proven to be applicable outside the research setting. If an intervention as defined above is determined to be Experimental/Investigative at the time of Service, it will not receive retroactive coverage even if it is found to be in accordance with the above criteria at a later date.
Experimental. The Seebeck coefficient was measured using a home-made sample holder built on a PPMS puck. It consists of two copper blocks separated by a thermal insulator plastic. The copper has a high thermal conductance so the blocks are at a uniform temperature while a temperature gradient is produced be- tween them. A small heater (maximum power of 5 W) is installed in the upper block. Its temperature is measured with a Pt-100 resistor and controlled with an external temperature controller. The temperature of the lower block is controlled by the set point of the PPMS, but the temperature was separately measured by a second Pt-100 resistor. The whole setup is covered with a stainless steal cup that isolates the sample holder to help stabilize the tem- perature gradient. The measurements were done in a relatively low vacuum of 10 mTorr. A schematic of the sample holder is given in Fig.6.1 The samples consisted of thin films, mostly on sapphire substrates, with an area of 10 × 10 mm2. CrO2 films were deposited by Chemical Vapor Deposition (CVD) on both isostructural TiO2(100) and sapphire (1000) sub- strates. CrO2 films deposit epitaxially on TiO2 in the form of rectangular grains aligned along c-axis but on sapphire the grains are aligned with six fold rotational symmetry coming from the hexagonal structure of the substrate, as detailed in Chapter 3. The Py thin films were deposited using dc sputter- ing in a UHV sputtering system, with a base pressure of 10−9 mbar, the Co films were deposited in Z-400 an RF sputtering system with base pressure of 10−6 mbar. Both Py and Co were deposited on sapphire substrates because of its better thermal conductivity. The Seebeck coefficient was recorded with reference to copper since Cu wires were connected at both ends of the film via pressed Indium. The po- tential difference was probed using a Nanovoltmeter (Xxxxxxxx 2018) in an open circuit geometry (J = 0). A dynamic technique was utilized to measure TEM as function of temperature in which the temperature difference between hot and cold point was always 5 K, while the temperature of the cold point was increased by 10 K in each step. In this way hot point and cold point interchanged in each step between the temperature range of 100 - 400 K [80]. To check the setup, TEP was measured for nonmagnetic Cu, Au, and Pt with reference to Cu. In principal, it should give a zero TEP on a Cu thin film, but we measured around 2.5 µV at temperature difference of 45 K with the hot terminal b...
Experimental. PLAN The experimental details that follow are approximate and may be changed upon mutual agreement of the NCI and Kite. Any change in the scope of this CRADA will be by mutual consent and written Amendment to the CRADA. […***…]. […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 28 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 29 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 30 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 31 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 32 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 33 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 34 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH […***…]. DESCRIPTION OF THE CONTRIBUTIONS AND RESPONSIBILITIES OF THE PARTIES — […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 35 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH — […***…]. — […***…]. — […***…]. PHS ICT-CRADA Case Ref. No. MODEL ADOPTED June 18, 2009 Page 36 of 52 Confidential PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH — […***…]. RELATED NCI AND COLLABORATOR AGREEMENTS: NONE RELATED INTELLECTUAL PROPERTY AND BUSINESS/SCIENTIFIC EXPERTISE OF THE PARTIES
Experimental. Materials and reagents Physical measurements
Experimental. Materials: 2%, 6% and 10% weight cobalt loaded silica aerogel samples were prepared by Xxxx. Xxxxxx’x lab. Ferrocene and ruthenocene loaded silica aerogel samples were provided by Xxxx. Xxxxx’x lab. NMR experiments: All the NMR experiments were carried out on a Chemagnetics CMX-200 spectrometer with a 7.5mm PENCIL rotor probe. The samples were ground into powder before packing into the rotor. Most of the samples were packed at ambient condition except the ferrocene and ruthenocene loaded silica aerogel sample which were packed in a glove box filled with nitrogen gas. A single pulse sequence was applied to observe 29Si NMR spectra, while 13C NMR spectra of the ferrocene and ruthenocene loaded aerogel samples were obtained using CP (cross polarization) and CP/MAS (magic angle spinning) techniques. The 29Si T1 was measured by the saturation recovery method.
Experimental. Materials and reagents Physical measurements [Ru(apy)(tpy)(9-EtGua)]2+ titration Synthesis and characterization of [Ru(apy)(tpy)(9-EtGua)](ClO4)2
Experimental. The parties have agreed that it is in their mutual interest to establish a new Internet provision as described below. In doing so, the parties recognize that the Internet as an advertising medium is still in its early stage of development. Accordingly, this provision is entered into on an experimental basis with the expectation and understanding that the parties will continue to assess such Internet development during the term of this Agreement with a view toward making such changes as are mutually beneficial in the next round of collective bargaining. Upon the request of either party, the parties will hold a Joint Industry-Federation Committee meeting during the term of this Agreement to discuss Internet-related issues.
Experimental. INVESTIGATIONAL: A drug, device, or dental treatment or procedure is experimentalƒinvestigational if:
a. The drug or device cannot be lawfully marketed without approval of the U.S. Food and Drug Administration and approval for marketing has not been given at the time the drug or device is furnished; or
b. Reliable Evidence shows that:
1) The drug, device, or dental treatment or procedure is the subject of ongoing phase I, II, or III clinical trials or under study to determine its maximum tolerated dose, its toxicity, its safety, its efficacy, or its efficacy as compared with the standard means of treatment or diagnosis; or
2) The consensus among appropriately qualified consultants of the Plan regarding the drug, device, or dental treatment or procedure is that further studies or clinical trials are necessary to determine its maximum tolerated dose, its toxicity, its efficacy, or its efficacy as compared with the standard means of treatment.
Experimental. The analytical techniques employed in these studies are: (i) X-ray diffraction (XRD) for phase identification and crystallite size determination; (ii) Variable temperature EMR (Electron Magnetic Resonance) studies to determine the electronic states; (iii) Variable temperature magnetometry to determine electronic states, magnetic phases and their concentration; (iv) FTIR/Photoacoustic spectroscopy to determine the structural aspects of surface species.
